Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus MMF versus everolimus plus reduced tacrolimus for renal function preservation after liver transplantation
2015-000590-12Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2015
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus, mycophenolate mofetil, mycophenolate sodium and tacrolimus (2 arms), sponsored by Novartis. Primary endpoint: Renal function preservation at Month 6. Started Jul 2015; status: completed.
02
Drugs
everolimusmycophenolate mofetilmycophenolate sodiumtacrolimus
Beyond the preview
Go deeper on 2015-000590-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000590-12.